lifestyle.newsblaze.com

Author: Biolojic Design

Biolojic Design Presents New Preclinical Data for BD200, a First-in-Class Multibody-Drug Conjugate Targeting Trop-2 and Nectin-4 at the American Association of Cancer Research Annual Meeting

April 17, 2026
Biolojic Design Earns Preclinical Milestone from Teva for First AI-Designed Multibody in Autoimmune Disease, TEV ‘325 (formerly BD9)

March 25, 2026